文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤放疗物理与技术

现代放疗时代寡复发与寡转移性宫颈癌的再程放疗

Re-irradiation in oligorecurrence and oligometastatic cervical cancer in modern radiotherapy era.
PubMed 文献 · Radiat Oncol · 2025-11-13

本回顾性研究纳入20例寡复发或寡转移(≤5个病灶)宫颈癌患者,接受至少一程现代再程放疗。中位随访33.6个月,首次复发后PFS、LRRFS、DMFS和OS分别为31.8%、33.6%、60.5%和84.2%,≥2级泌尿、胃肠和血液毒性分别为40%、25%和55%,无≥3级泌尿或胃肠毒性。

要点

  • 现代再程放疗对selected寡复发/寡转移宫颈癌可行有效,生存获益良好。
  • ≥3级血液毒性25%,多发生于化疗期间;无≥3级泌尿或胃肠毒性。
  • SBRT、VMAT和MR引导自适应近距离放疗是主要再程放疗技术。

核心结论

  • 现代放疗技术再程放疗是selected局限性复发或转移性宫颈癌可行且有效的挽救治疗选择,生存获益良好且毒性可接受。

研究设计与样本

  • 回顾性研究纳入20例寡复发或同时/异时寡转移(≤5个病灶)宫颈癌患者,均接受至少一程再程放疗。
  • 采用Kaplan-Meier法估计LRRFS、DMFS、PFS和OS,按CTCAE 5.0版评估泌尿、胃肠和血液毒性。

主要发现

  • 中位年龄53岁(范围33-70),75%初诊为FIGO 2018 III期,鳞癌50%、腺癌45%。
  • 复发最常见于盆腔(30%)和腹主动脉旁(30%)淋巴结,50%为野内复发。
  • 首次和第二次复发中位时间分别为11.1个月(IQR 6.0-17.3)和13.7个月(IQR 5.6-21.7)。
  • 中位随访33.6个月,首次复发后PFS、LRRFS、DMFS和OS分别为31.8%、33.6%、60.5%和84.2%。
  • ≥2级泌尿、胃肠和血液毒性分别为40%、25%和55%;≥3级血液毒性25%,无≥3级泌尿或胃肠毒性。

关键数值与推荐

  • 再程放疗后膀胱、直肠、乙状结肠和肠道野内/野外平均累积D0.03 cc分别为83.8±6.7/78.5±7.5、71.2±3.9/69.5±5.2、68.0±5.5/61.0±5.3和62.9±4.6/62.4±7.1 GyEQD2(3)。
  • SBRT、VMAT和MR-GABT是最常用再程放疗技术,用于95%患者。

临床怎么用

  • 对selected寡复发或寡转移(≤5个病灶)宫颈癌患者,可考虑现代技术再程放疗作为挽救治疗。
  • 再程放疗期间需关注血液毒性,尤其同步化疗时;泌尿和胃肠毒性以低级别为主。

局限性

  • 回顾性设计、样本量小(20例),结论需谨慎推广。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recurrent cervical cancer remains a therapeutic challenge despite advances in primary treatment. The emerging paradigm of oligorecurrence and oligometastasis has opened avenues for curative-intent local therapies, including re-irradiation. Modern radiotherapy techniques have enabled high-dose delivery with acceptable toxicity. This study aims to assess clinical outcomes and treatment-related toxicities in patients with oligorecurrent or oligometastatic cervical cancer treated with modern re-irradiation techniques. METHODS: This retrospective study included 20 cervical cancer patients with oligorecurrence or synchronous/metachronous oligometastases (≤ 5 lesions) who underwent at least one course of re-irradiation. Survival outcomes including locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS) were estimated using Kaplan-Meier analysis. Genitourinary (GU), gastrointestinal (GI), and hematologic toxicities were assessed and graded based on CTCAE version 5.0. RESULTS: The median age was 53 years (range: 33-70), with 75% initially diagnosed at FIGO 2018 stage III. The predominant histologies were squamous cell carcinoma (50%) and adenocarcinoma (45%). Recurrences most commonly involved pelvic (30%) and para-aortic (30%) lymph nodes, with 50% occurring in-field. Stereotactic body radiotherapy (SBRT), volumetric modulated arc therapy (VMAT), and MR-guided adaptive brachytherapy (MR-GABT) were the most commonly used re-irradiation modalities, employed in 95% of patients. Median times to first and second recurrence were 11.1 months (IQR: 6.0-17.3) and 13.7 months (IQR: 5.6-21.7), respectively. At a median follow-up of 33.6 months, PFS, LRRFS, DMFS, and OS rates after the first recurrence were were 31.8%, 33.6%, 60.5%, and 84.2% respectively. Grade ≥ 2 genitourinary (GU), gastrointestinal (GI), and hematologic toxicities were observed in 40%, 25%, and 55% of patients, respectively. Grade 3 hematologic toxiciy was 25% and mostly occurred during chemotherapy administration. No grade ≥ 3 GU or GI toxicities were reported. The mean accumulated D0.03 cc after re-irradiation to bladder, rectum, sigmoid and bowel for in-fied/out-of-field were 83.8 ± 6.7/78.5 ± 7.5), 71.2 ± 3.9/69.5 ± 5.2, 68.0 ± 5.5/61.0 ± 5.3, and 62.9 ± 4.6/62.4 ± 7.1 GyEQD2(3), respectively. CONCLUSION: Re-irradiation with contemporary radiotherapy techniques appears to be a feasible and effective salvage option for selected patients with limited recurrent or metastatic cervical cancer, yielding favorable survival and acceptable toxicity profiles.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sittiwong W, Prasartseree T, Tuntapakul P, et al. Re-irradiation in oligorecurrence and oligometastatic cervical cancer in modern radiotherapy era. Radiat Oncol. 2025. PMID: 41225583. doi:10.1186/s13014-025-02747-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。